Argentina continues to be the third largest producer of biotech crops after the United States and Brazil, producing 15 percent of the world´s total biotech crops.
THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY
USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT
Required Report - public distribution
GAIN Report Number:
Agricultural Biotechnology Annual
Argentina Biotechnology Annual Report
Melinda D. Sallyards
Argentina continues to be the third largest producer of biotech crops after the United States and Brazil, producing 15 percent
of the world´s total biotech crops.
On March 16, 2012, The Government of Argentina announced the implementation of the new regulatory framework for
agricultural biotechnology. The goal with this revamped regulatory system is to reduce the approval time for new events to
Argentina is willing to take the lead in the region in the development and use of new technologies. This has been
demonstrated this current year by the approval of Syngenta’s quadruple corn event which was approved before Brazil, and
the development of new genetically engineered (GE) seeds with drought resistance created by Argentine researchers. This
focus on biotechnology was further highlighted by a recent trade mission to Brazil to explore a joint venture of GE drought
resistant sugar cane variety. Furthermore within the last month the industry has announced substantial investment in the
Even when intellectual property rights (IPR) continues to be an unresolved issue in Argentina, the private agreement
developed by Monsanto in 2011, continues to be a successful model.
Section I. Executive Summary:
Argentina continues to be the third largest producer of biotech crops after the United States and Brazil, producing 15 percent
of the world´s total biotech crops. The country´s area cultivated with biotech varieties in MY2011/12 is 23.6 million
hectares, 800,000 more hectares from the previous year (an increase of 3.2 percent). Almost all soybean area is planted with
biotech seed varieties, while 92 percent of corn area and 100 percent of cotton area are biotech varieties.
On March 16, 2012, the Government of Argentina (GOA) announced the implementation of the new regulatory framework
for agricultural biotechnology. The goal with this revamped regulatory system is to reduce the approval time for new events
to 24 months, while before the average was 42 months.
Argentina has a clear intention to be in the forefront in the introduction of innovative technologies to farmers and this has
been demonstrated in several ways: the approval of Syngenta’s quadruple corn event which was approved before Brazil: a
trade mission to Brazil to explore a joint venture of a GE drought resistant sugar cane variety; new GE seeds with drought
resistance created by Argentine researchers; and the announcement of industry’s substantial investment in the country.
Argentina continues to be an important ally of the United States in international issues involving biotechnology and was co-
complainant with the United States in the World Trade Organization challenge to the European Union moratorium on biotech
crop applications. While the lack of a royalty collection system is still an important issue, the GOA has placed a priority on
stimulating biotech research and innovation.
The Argentine Seed Law allows producers to successively use seeds on their own farms. Farmers cannot sell these seeds.
This law is interpreted to mean that farmers only have to pay royalties on the original purchase of biotech seeds, but not
when they replant seeds that have been selected and saved. According to official numbers, 20 percent of the total area
planted with soybeans in Argentina is sown with seeds purchased from authorized dealers; 30 percent with seeds saved by
farmers for their own use, and the remaining 50 percent with seeds selected and sold illegally.
Although intellectual property rights (IPR) continues to be an unresolved issue in Argentina. However, in an effort to move
forward in finding a mechanism to recognize IPR in order to allow the country to obtain the new soybean varieties, in 2011
Monsanto (supported by the seed industry) developed a private agreement with farmers. The agreement is based on an
“intention letter” where the farmers express their willingness to have access to the Round Up Ready 2Y and the Round Up
Ready 2YBt soybeans, and commit to pay royalties if they use any of those varieties. The system does not apply to the first
generation of the Roundup Ready technology (known as the 40-3-2 event). Monsanto reports that 8000 farmers have already
signed the agreement, proving to be a successful alternative in allowing new varieties in Argentina.
Argentina is active in development of genetically engineered animals for production of pharmaceutical products, but has not
approved any genetically modified animals for food consumption (seed Section VI Animal Biotechnology).
Section II. Plant Biotechnology Trade and Production:
Argentina is the world's third largest producer of biotech crops after the United States and Brazil, with twenty four biotech
crop varieties approved for production and commercialization: three for soybeans, eighteen for corn, and three for cotton
(please see complete list of biotech crops approved in Argentina at the end of this section).
Introduction of biotech soybeans in the late 1990s sparked a rapid expansion of soybean production, which now surpasses
18.8 million hectares. The country´s area cultivated with biotech varieties in MY 2011/12 is 23.6 million hectares, 800,000
more hectares from the previous year (an increase of 3.2 percent).
Argentina, Evolution of GE Area
SOYBEANS CORN COTTON
Source; Argenbio 2012
Released in 1996, glyphosate tolerant (Roundup Ready) soybeans were the first biotech crop introduced into Argentine
agriculture. Since its release, this technology has been adopted at a very high rate, with almost all of the 18.8 million
hectares of soybeans planted for the 2011/2012 season being biotech. The new technology facilitated the incorporation of
double crop soybeans (allowing soybeans to be planted following wheat harvest) in many areas where only one crop was
planted before the availability of the biotech varieties.
The Argentine soybean economy is geared almost entirely towards exports, with 20 percent exported as soybeans and the rest
processed by the oilseed crushing industry. Ninety-three percent of soybean oil and ninety-nine percent of by-products
(meals) are exported.
Monsanto announced that they expect their Bt x RR2 event (resistant to herbicide and insects) to be commercially approved
for the next crop season (2012/2013). The company already holds the local patent for this event. In the past, the company
failed to obtain a local patent for the RR event introduced in Argentina 15 years ago and its efforts to collect royalties have
been frustrated by local regulations. However, Monsanto says it is making
progress in reaching an agreement with farmers to pay royalties before introducing the new, improved variety of soybean
seeds. The company plans to launch the new variety in the Northern provinces of Argentina first, and later in the rest of the
(Please see details of the agreement signed by Monsanto & farmers under “Royalties”, Section III, Biotechnology Policy of
For more detailed information on soybean production, Please see the Argentina Oilseeds and Products Annual Report in the
Global Agricultural Information Network (GAIN) system.
This will be the fifth season where Argentine farmers used stacked corn events. In February 2007, the government simplified
the approval process for stacked events allowing applications for a transgenic crop combining two already approved events
without a full analysis of the new crop. On August 31, 2007 Argentina approved the first stacked gene, Monsanto’s
The most recent approval is Syngena’s Bt11 x MIR162 x GA21 x MIR 604 quadruple stack corn. Previously, Syngenta’s
triple stack corn seed with herbicide tolerance and above-ground insect control was approved in November 2011. The
addition of the MIR604 trait will represent an important tool for growers to combat the increasing presence of corn rootworm
in Argentina increases.
Biotech corn adoption represents 92 percent of total corn planted area, 4.2 million hectares. In the 2011/2012 crop season the
area planted with stacked events (Bt x TH) accounted for 57 percent of the total area (approx 2.4 million hectares). The rest
of the biotech corn planted corresponded to Bt, estimated in 1.4 million hectares, representing approx 33 percent, and
glyphosate tolerant variety (GA 21) with 400,000 hectares planted, corresponding to 10 percent of the total biotech corn.
For more detailed information on corn production, Please see the Argentina Grain & Feed Annual Report in the Global
Agricultural Information Network (GAIN) system.
Biotech cotton adoption represents 100 percent of total cotton planted area (575,000 hectares). In the 2011/12 crop season
88 percent (506,000 hectares) was planted with the stacked event (Bt x TH), and 12 percent (69,000 hectares) was planted
with the glyphosate resistant event (TH).
In December 2009, Argentina approved the first cotton stacked gene, Monsanto’s MON 1445 x Mon 531 (glyphosate
tolerance and resistance to Lepidoptera). The graphics below show the high rate of adoption of this event by the Argentine
News – New Initiatives
Argentina has a clear intention to be in the forefront in the introduction of innovative technologies to farmers and this is
demonstrated in several ways, such as the approval of Syngenta’s quadruple corn event which was approved before Brazil, a
trade mission to Brazil to explore a joint venture of a GE drought resistant sugar cane variety, new GE seeds with drought
resistance created by Argentine researchers, and industry’s recent announcement of proyected large investment in the
Approval of Syngenta’s quadruple stacked corn event
Argentine Secretary of Agriculture Lorenzo Basso announced on March 22, 2012, the official approval for Syngenta’s
MIR604 corn rootworm trait, and for its Bt11 x MIR162 x GA21 x MIR 604 quadruple stack corn. The approval of this
quadruple stack event, not yet approved in Brazil, shows that Argentina is anxious to again take the lead in the region in the
development and use of new technologies.
GE Sugar variety- Argentine Mission to Brazil
The Argentine mission led by high level officials from the Argentine Ministry of Agriculture and accompanied by industry
representatives and researchers, evaluated the possibility of a private joint venture with Brazilian industry in developing a
GE drought resistant sugar cane variety. Brazilian researchers are already working on the development of this variety, and
with the input of Argentine researchers they might have it ready by the beginning of 2013. However, approval is not
expected until 2017, at the earliest. The Argentine industry expressed interest in this trait due to its potential to increase the
current sugar cane planted area of 350,000 hectares to an estimated planted area of 5 million hectares in ten years from now.
This increase in production would be mainly used for ethanol production. Mission members expressed confidence that the
agreement with Brazil would be signed shortly.
In the meantime, the Argentine National Advisory Committee on Agricultural Biotechnology (CONABIA) is already
evaluating applications for the Round-Up Ready (RR) and the Bt sugar cane varieties. Both varieties have been developed by
Argentine scientists from Obispo Colombres Experimental Research Station, and Santa Rosa Research Institute. It is
estimated that the commercial approval for the RR variety may be granted in 2014. The GE sugar cane has not been
approved yet in any country; therefore, if approved in 2014, Argentina would be the first country in the world.
Industry’s investments in Argentina
On June 15th,2012, Monsanto announced an investment of US$ 355 million to build a new corn-seed-production plant in
Argentina. The plant will be in Cordoba province and it is expected to be finalized in December 2013. As reported by
Monsanto representatives, this investment will increase the company’s capacity in Argentina by 80 percent. Less than a
month later, On July 5th, the Swiss company Syngenta announced they will invest US$ 175 million to boost their seed-
production capacity in Argentina by building a new plant. The new facility will be built in Cordoba province as well, and
will produce annually one million bags of corn and sunflower seeds.
New GE seeds with drought tolerance
Argentine researchers have isolated the drought tolerance gene from sunflowers, and they have inserted it in varieties of
corn, wheat and soybeans with promising results. It has been reported that after three years of field testing in different
regions of the country (with different soil conditions and different climates), yields are between 15 and a 100 percent higher
than regular. The Argentine firm Bioceres, who has been granted a license for the use and exploitation of this gene, signed a
joint venture agreement with the U.S. Company Arcadia Biosciences. When consulted, representatives of the this new
partnership named Verdeca, expressed that they expect to have the new seeds in the market by 2015 or 2016, as two or three
more years of environmental and nutritional testing will be required before the new seeds obtain the commercial approval.
These new varieties will be an important
milestone for the Argentine agricultural sector since they will help confront the effects of the climate change.
GE potatoes with virus resistance and herbicide tolerance
According to contacts within the industry, it is estimated that GE potatoes with virus resistance (Potato Virus Y PVY, and
Potato Leaf Roll Virus PLRV) and herbicide tolerance that are under CONABIA´s evaluation at the moment, might be
commercially approved in 2013. These viruses may cause crop losses of up to 70 percent in Argentina, and therefore this
approval may be an important improvement for the potato industry.
Biotech Crops Approved in Argentina
Crop Trait Category Event Applicant Resolution
Soybean Glypohosate Herbicide Tole "40-3-2" Nidera S. A. rant (25-3-96)
Soybean Resistant to Glufosinate Amon 2704-12 Bayer S.A. (2011) ium A
Soybean Resistant to Glufosinate Amon 447-127 Bayer S.A. (2011) ium A5
Cotton Resistant to Lepidoptera "MON 531" Argentina
Cot lypohosate He
ton G Tole N 1445" Argentina ran "MOt S.A.I.C. (25-4-01).
Cot to Lepidoptera ton Resistant and 1445 x MON 531 Monsanto Glyphosate Toleran MON t
Corn Resistant to Lepidoptera Ciba-Ge igy
Corn Glufosinate Amonium Tole 5" AgrEvo S
ran "T2t (23-6-98)
Corn Resistant to Lepidop tera "MON 810" Argentina
Corn Resistant to Lepidop rtis tera " Bt 11 Nova"
Agrosem S.A. (27-7-01).
Corn Glypohosate Herbicide Tole " NK 603 " Argen
rant S.A.I.C. (13-7-04).
Re AgroSciences sistant to Lepidoptera
Corn S.A. and Glufosinate Amonium “TC 1507”
Tole and rant Pioneer
Corn Glypohosate Herbicide Syngenta Tolerant Seeds S.A.
Corn NK603x Tolerant and Resistant to Monsanto
Lepidopte MON810 ra
Re AgroSciences sistant to Lepidoptera S.A.
Corn and Glufosinate Amon 1507 x NK603 y ium and Glyphosate
Tole Pioneer rant Argentina
Corn Tolerant and Resistant to Bt11 ta x GA21 Syngen
Lepidopte Seeds S.A.
Corn Resistant to Lepidoptera "Mon89034" Monsanto
Corn Tolerant and Resistant to "Mon 88017 Monsanto
Corn Tolerant and Resistant to a Agro Lepidopte "Mon89034x88017
ra and S.A.
Corn Resistant to Lepidop o tera MIR genta Agr 162 Syn S.A.
Resistant to Lepidoptera
Corn and Glypohosate and G 2
lufosinate Bt11xGA21xMIR16 Herbicide S.A.
Glifosate tolerant and
Corn herbicides that inh ibit DP-098140 Pionneer Arg.-6
Corn Resistant to Coleoptera MIR 604 Syngenta Agro S (2012) .A.
Corn Resistant to Lepidoptera and MIR162xMIR604xGA21 Syngenta (2012) Coleoptera, and Bt11x
Glypohosate and Agro S.A.
For a complete list of evaluations, please visit: http://www.minagri.gob.ar/SAGPyA/areas/biotecnologia/
Section III. Plant Biotechnology Policy:
New Regulatory Framework for Agricultural Biotechnology in Argentina
On March 16, 2012, Argentine Secretary of Agriculture Lorenzo Basso announced the implementation of the new regulatory
framework for agricultural biotechnology in Argentina. The goal with this revamped regulatory system is to reduce the
approval time for new events to 24 months. Before the implementation of the new regulatory framework, the approval
process used to take approximately 42 months, which is considered very long taking into account the current dynamics of the
biotech industry and the fact that Brazil is approving trials at a faster rate than Argentina. According to contacts within the
National Advisory Committee on Agricultural Biotechnology (CONABIA), the flow of applications has tripled since
1999, while outdated regulations held back field trails and commercial release.
This new framework was a result of a two year long coordinated effort by many sectors in Argentina. In December 2010
Argentine Secretary of Agriculture Lorenzo Basso signed an agreement with the Argentine Seed Association (ASA) to
develop a working plan to identify the problems in the Argentine regulatory system. To comply with this goal they created
five working groups where each group analyzed a different phase of the approval process, and developed proposals to
improve its efficiency.
The groups conducted about 50 meetings and 2 workshops during 2011, and they focused on three main points: reduction of
the administrative process, easy access to the evaluation process, and coordination of the different agencies regarding the
information required on each stage. The outcome of this coordinated effort is the new regulatory framework announced by
Secretary Basso on March 2012.
The evaluation of new events takes place on a case-by-case basis, taking into consideration the process only in those cases
where the environment, the agricultural production or the
health of humans or animals could be at risk, applying scientific and technical criteria. The Argentine regulation is based
upon the characteristics and behaviors identified in the GE event. Regarding the processes used to obtain it, the aspects that
may differ with the behavior of the same non-GE organism (conventional counterpart) are taken into consideration, both
regarding the agroecosystem as well as its safety as food for human and animal consumption.
The key office within the Ministry of Agriculture that centralizes all biotech activities and information is the Biotechnology
Direction, created in 2009. This office coordinates three technical areas: biosafety issues (the head is a member of the
National Advisory Committee on Agricultural Biotechnology, CONABIA), policy analysis and formulation, and regulatory
The approval process for commercialization of biotech seeds involves the following agencies within the Ministry of
-National Advisory Committee on Agricultural Biotechnology (CONABIA)
Role: Evaluate impact in the agricultural ecosystem. Its main responsibility is to assess, from a technical and scientific
perspective, the potential environmental impact of the introduction of biotech crops in Argentine agriculture. CONABIA
reviews and advises the Secretariat on issues related to trials and/or the release into the environment of biotech crops and
other products that may be derived from or contain biotech crops. It is a multi-sectorial organization made up by
representatives from the public sector, academia and private sector organizations related to agricultural biotechnology.
CONABIA members perform their duties as individuals and not as representatives of the sector they represent, and they are
active participants in the international debate on biosafety and the related regulatory processes. It ensures compliance with
Resolutions 701/2011 and 661/2011 (please see links below). These new resolutions supersede Resolution 39/2003.
CONABIA is a multidisciplinary and inter-institutional organization with advisory duties.
Under the new regulatory framework, the evaluation time for CONABIA is now set at 180 days. Previously there was no
timeframe and the approval by this agency could take up to two years. Another difference with the new regulatory system is
the inclusion of an instance of prior consultation. Also, the use of electronic forms has been included, where before the
companies had to hand deliver documents. This will allow all agencies to access documents at the same time, further
speeding up the approval process.
CONABIA has reviewed over 1200 permit applications since its creation, developing new capacities as the sector required.
CONABIA is an advisory agency that operates pursuant to a resolution by the Argentine Ministry of Agriculture. In absence
of a law governing its reviews, there are limits in its ability to penalize those who do not comply with stipulated procedures.
Resolutions 701/2011 and 661/2011: http://www.senasa.gov.ar/contenido.php?to=n&in=1001&ino=1001&io=18873
-National Service of Agricultural and Food Health and Quality (SENASA)
Role: Evaluate the biosafety of food products derived from biotech crops for human and animal consumption.
-National Direction of Agricultural Food Markets (DNMA)
Role: Evaluate commercial impact on export markets by preparing a technical report in order to avoid a negative impact on
Argentine exports. DNMA mainly analyzes the status of the event under study in the destination markets. They focus on
whether the product has been approved or not and, as a result, whether the addition of this event to Argentina’s export
supplies might represent a potential barrier to the access to these markets. Under the new framework, the DNMA will
evaluate the commercial impact on export markets within 45 days. Again, previously there was no time frame for this
-National Seed Institute (INASE)
Role: Establish requirements for registration in the National Registry of Cultivars.
Upon completion of all of the steps mentioned above, CONABIA's Office of Technical Coordination compiles all pertinent
information and prepares a final report to the Secretary of Agriculture, Livestock, Fisheries and Food for final decision.
There is no official system in place. At this stage, only private companies (authorized labs) have the capability to perform the
required tests. For example, the National Institute of Agricultural Technology (INTA) does analysis on a private basis.
There is no specific regulation in Argentina in reference to labeling biotech products. The current regulatory system is based
on the characteristics and identified risks of the product and not in the production process of that product.
The policy of the Ministry of Agriculture on labeling in international fora is that it should be based on the type of food
product derived from a specific biotech seed taking into account that:
Any food product obtained through biotechnology and substantially equivalent to a conventional food product,
should not be subject to any specific mandatory label.
Any food product obtained through biotechnology and substantially different from a conventional food product for
any specific characteristic may be labeled according to its characteristics as food product, not according to aspects
concerning the environment or production process.
Differential labeling is not justified, as there is no evidence that demonstrates that food products produced through
biotechnology may represent any risk for the consumers’ health.
In the case of agricultural products, as the majority of them are commodities; the identification process would be
complicated and expensive. The increased production costs as a result of labeling would end up being paid by the
consumers, without assuring that this would represent better information or increased food security.
Approval of stacked events is based in a case by case evaluation under which the applicant needs to submit a letter
simultaneously to the Ministry of Agriculture (Direction of
Biotechnolgy) and to the National Service of Agricultural and Food Health and Quality (SENASA) requesting authorization
for commercialization of the specific stacked event.
The evaluation is based on possible metabolic interactions between the individual events contained in the stacked event.
Also, in order to evaluate the possible effects of the stacked event in the ecosystem, as well as the food biosafety evaluation,
CONABIA and/or SENASA will determine whether they request additional information from the applicant.
Intellectual Property Rights – Royalties
Argentina is a major producer and exporter of agricultural biotechnology products, yet it does not have an adequate and
effective system in place to protect the intellectual property rights of new plant varieties or plant-related technology.
Penalties for unauthorized use of protected seed varieties are negligible. Judicial enforcement procedures in Argentina
likewise are ineffective as a mechanism to prevent the unauthorized commercial use of protected varieties.
Argentine Intellectual Property (IP) laws are based on UPOV-78, which provides strong protection for the right of farmers to
save and replant seeds, and exempts them from providing explanations on how selected seeds were used. The lack of
effective enforcement options for plant variety rights, combined with the absence of patent protection for a significant range
of biotech inventions, renders Argentina’s intellectual property system inadequate from the perspective of the biotechnology
In January 2004, Monsanto announced that it would cease investments in and sales of RR soybeans in Argentina. The
central issue, according to Monsanto, was its inability to fully collect RR-technology-related royalties from Argentine
growers. Monsanto applied for and was denied a patent on RR soybeans, a decision it appealed unsuccessfully with the
Argentine Supreme Court. Argentine law currently allows farmers to save seed from one harvest and to use it the following
year if a royalty is paid to the original seed breeder. However, it is illegal to sell, trade, or pass saved seed from one producer
In May 2004, Argentina’s National Seed Institute implemented Resolution 44/2004, requiring that each sack of seed be
labeled with quantity, unit price, total sales price, and seed species, type or variety.
Due to continued illegal seed sales, Monsanto initiated legal actions in European Countries in 2005 against unlicensed
shipments of soybeans, soybean meal, and other soy products containing the RR gene, but was not successful in the legal
Agreement between Monsanto and the farmers
In 2011, and before bringing the new soybean RR2Y and/or RR2YBt technologies varieties to Argentina, Monsanto
developed a private agreement that is signed between the company and the farmers. Up until now, 8000 farmers have signed
the “letter of intention” which represents an area of 11 million hectares (60.7 percent of the total area). The system does not
apply to the first generation of the Roundup Ready technology (known as the 40-3-2 event).
In case the RR2Y and/or RR2YBt technologies are available in the country and if the farmers decide to use such
technologies they commit to:
Purchase soybeans containing Monsanto’s RR2Y and/or RR2YBt technologies from Monsanto or Licensees
authorized by Monsanto
Plant such seeds within the Argentine territory.
Commercialize grains obtained with those exporters or grain elevators participating in the system,
Pay the corresponding royalties for each use of such technologies upon the purchase of seed bags of certified
soybeans, or upon statement and planting of seeds for own use, or upon the delivery of such grains to the exporter or
grain elevator participating in the system,
Use the RR2Y and/or RR2YBt technologies pursuant to the commercialization system established by Monsanto,
which will be in line with the good agricultural practices system as defined by the Argentine Seed Association.
Locate geographically, along with Monsanto, the farmer’s plots during the planting of soybeans containing the
RR2Y and/or RR2YBt technologies.
Other considerations of the agreement:
Payment of royalties shall entitle the farmer to plant soybean seeds containing the RR2Y and/or RR2YBt
technologies in the country and commercialize a definite number of tons of grains harvested.
- Exporters and grain elevators participating in the system shall evaluate the presence of the RR2Y and/or RR2YBt technologies
in the grain they receive.
- Monsanto shall be entitled to evaluate the presence of the RR2Y and/or RR2YBt technologies in the farmer’s fields through
inspections and sample taking.
- In the event that royalties have not been paid before delivering the grains to the exporter/grain elevator participating in the
system, the amount due for royalties shall be received by such participant and sent to the supplier of the technology on behalf
of the farmer. That could lead to an adjustment in the grain transaction in order to reflect such payment.
This agreement does not represent a license or authorization to use of the RR2Y and/or RR2YBt technologies. The use of
such technologies shall be subject to the terms of the agreement and the corresponding license for commercial use.
Any controversy and/or dispute arising from or related to this agreement shall be resolved, at the discretion of any of the
parties, by the Grain Arbitration Chamber of the Rosario Board of Trade (Cámara Arbitral de Cereales de la Bolsa de
Comercio de Rosario) or by the Buenos Aires Grain Arbitration Chamber (Cámara Arbitral de Cereales de Buenos Aires).
Argentina does not have a biosafety law in place. Initial discussions on developing a biosaftey law took place in 2001, but
due to the institutional and economic crisis that broke out in December 2001, the draft was never discussed in Congress and
there is no evidence that it will be in the near future. Private sources have indicated that due to the current conditions at
Congress, a Biosafety Law is considered a long term objective.
International Negotiation Fora
Cartagena Biosafety Protocol
In the international biotechnology negotiation arena, the Cartagena Biosafety Protocol (CBP) is probably the most significant
issue. Argentina signed the Biosafety Protocol in May 2000
in Nairobi, Kenya, but has not yet signed its ratification. Argentina is still undergoing a consultation process, analyzing and
debating with all the involved sectors the position the country will take in this respect.
Codex Alimentarius and Other Agreements
During 2009 Argentina chaired the Codex working group on methods of analysis for GM foods. In addition, the country is
actively working to reach consensus on biotech labelling and actively participating to avoid potential trade disruptions and
unnecessary cost increases.
First Meeting of the Like-Minded Group on Innovative Agricultural Technologies with a focus on GE crops
A group of representatives of exporting countries met in Argentina in 2012 with the intention of setting the scope, aim and
priority issues of a like-minded group on innovative agricultural technologies with a focus on GE crops. Recognizing that
agricultural production will need to substantially increase to meet global food demand; understanding that innovative
agricultural technologies need to continue to play a critical role in addressing these challenges, and emphasizing the
regulatory approaches should be science based, the group was successful in setting the basis for collaborative work
especially in the areas of research and education, promotion of utilization of Codex regulations, and support of science based
assessments of food, feed and environmental safety.
InterAmerican Institute for Agricultural Cooperation (IICA) Workshop on Low Level Presence (LLP)
In an effort to review the status of the LLP situation in the different countries, IICA invited government representatives of
the IICA member countries, Canada and the United States to attend a two-day seminar to assess the potential impact of LLP
for parties involved in GE crops trade.
The objectives of the workshop were to develop a common understanding among IICA member countries on the issue of
LLP for food, feed and processing, to exchange views on how to internationally move the issue forward, and to support
ongoing LLP work on the Americas. Another issue of high importance discussed, was asynchronic approval of GE events in
the different countries. Relevant topics of discussion were:
Definition of LLP: All countries agreed that the initial step is to establish a common definition of LLP that sets thresholds, as
it is not yet defined by Codex Alimentarius.
Different levels of knowledge and implementation: it was clear that the level of knowledge on these issues varies significantly
from one country to another. A growing number of countries have established risk assessment procedures for approving the
import of GE crops. However, most of these countries have not, as yet, adapted these processes to address the potential LLP
in their imports of GE material already authorized and being produced in other countries, but not yet approved (and therefore
not intended to be present) in the importing country. This gap has the potential to cause significant trade disruptions.
Zero tolerance policy: Agricultural commodities inevitably mix to a small extent, therefore it is not possible to comply with a
zero tolerance policy. Industry can implement different strategies and adopt various operational changes to reduce, but not
eliminate, the likelihood
of LLP. However, it must be noticed that lower thresholds incur higher additional costs as development, production, and
distribution expenditures rise.
Sharing information: the representatives recognized the common need to share information and to develop capacity building.
Knowing what the other countries are working on will not only help to improve synchronized approvals but also to
harmonize procedures internationally.
Global policy: the representatives support the need to have a global policy on the issue that will allow having a common
The conclusions of the workshop were that LLP and asynchronic approvals are becoming of high importance for all the
represented countries due to the increasing level of regional and international trade of GE commodities. In order to comply
with the objectives, the governments intend to work together to promote the development of a global policy, and to make the
initial steps to create a system that would allow sharing of information.
Ongoing Issues at National Level
The GOA 15 year Strategic Plan
The plan proposes to diversify the application of biotechnology, both in the number of tools and in productive activities. It
advocates creating an appropriate environment (in political, legal and public acceptance issues) for the creation and
development of biotechnology-based companies, and also to improve the consolidation of the existing ones. It proposes to
assist increasing agricultural production, while preserving and improving the quality of life of the present and future
generations. One of the strengths of the plan resides on its flexibility: the accomplishment of the plan has been based on the
implementation of a scheme that is built almost simultaneously along its execution, including the revision of objectives,
goals and main actions.
Argentine Biotech Chamber
In December 2011, a group of private companies with support of the Ministry of Science and Technology, and several
Argentine Universities, announced the creation of the Argentine Chamber of Biotechnology. Argentina has a strong
institutional platform, both in the public and private sectors, and the objective of the newly launched chamber is to promote
the development of a public-private synergy in the area of biotechnology, where Argentina has strong competitive
advantages due to its natural, human and scientific resources. It is a multi-sectorial organization made up by representatives
of the food industry, animal and plant health, diagnosis, agricultural and forestry industry and biofuels. As its first initiative,
the chamber will conduct a survey among all the companies that have some biotech related activity with the intention of
developing a comprehensive ¨map¨ of the scientific, commercial and technological availability in the country.
Section IV. Plant Biotechnology Marketing Issues:
Public Perception – Consumer’s Attitude
Most Argentine scientists and farmers are optimistic and enthusiastic about the prospects of using biotechnology to improve
yields and nutritional value of crops while decreasing the input of chemical pesticides. Argentine consumers do not see
biotech products as a benefit
to themselves but they can see these products as economically productive to farmers and multinational seed companies.
Therefore Argentine consumers are still hesitant about supporting the technology. As Argentina has been a leader in the
adoption of biotechnology, there is a need for dialogue and communication among scientists, farmers, private companies,
consumers, government, and regulatory organizations.
After Monsanto’s announcement of its new plant in Cordoba province (please see Section II Biotechnology Trade &
Production in this report) several NGOs and consumer associations expressed deep concern and have published several
articles about possible negative impacts on human health and the environment. They mainly question the potential for
contamination, toxicity and allergenicity of biotech products.
Public Participation, Education and Awareness Activities
In 2004 the GOA included biotechnology as a mandatory subject in schools, but most teachers did not have any training or
access to sources for information. At that time a panel of experts from Argenbio (the national nonprofit biotechnology
association) designed a training course and educational materials that are now offered free of charge to schools around the
country. As of today, more than 11,000 teachers have received the “Por qué Biotecnología” (Why Biotechnology) training.
Section V. Plant Biotechnology Capacity Building and Outreach:
FAS Buenos Aires organized and accompanied a group of Argentine journalists to the United States to demonstrate how the
United States uses and regulates agricultural biotechnology.
FAS Buenos Aires selected and facilitated the trip of an Argentine expert who was key speaker of a biotech Conference held
in South Africa, Mozambique and Madagascar.
A. Ag Counselor participated as speaker of the Biotech Forum in Rosario, Santa Fe Province.
B. FAS Buenos Aires sponsored a trip for Argentine biotech expert to participate in a hemispheric seminar organized
by the US Codex Office in Lima, Peru.
FAS Buenos Aires coordinated a trip for five Argentine biotech experts to participate in a hemispheric meeting organized by
the US Codex Office in Panama City, Panama.
FAS Buenos Aires coordinated a trip along with the United Soybean Board for 2 Argentine farmers to participate of the
“Farmer to Farmer” workshop held in Asuncion, Paraguay.
The Argentine Ministry of Agriculture and FAS Buenos Aires coordinated the First Meeting of the Like-Minded Group on
Innovative Agricultural Technologies with a focus on GE crops.
FAS Buenos Aires proposes a continuation of education and outreach as well as a more targeted information campaign.
Specific activities may include:
- Workshops in different cities to target audiences around the country,
- A two-day conference directed mainly to Congressmen, but also to media, academia and government officials among
- Activities with local universities to demonstrate the benefits of Biotechnology in Argentina
- Continue Cooperator, Cochran, and International Visitor program activities,
- Special activities designed for consumer association leaders and consumers in general,
- Workshops especially directed to medical doctors and nutritionists, explaining the innocuousness of biotech products;
- Workshop in risk assessment that will be directed to Argentine, Paraguayan and Uruguayan experts.
- Technical workshop to discuss treatment and analysis of stacked biotech events.
- Work with Senators and Representatives on the regional forum created after the Southern Cone Reverse CODEL; and,
- Meetings to develop lines of communication between the GOA and the USG during the review process of biotech events.
Section VI. Animal Biotechnology:
I. Development and Use
Argentina was the first country in Latin America to develop two generations of genetically modified cows capable of
producing Human Growth Hormone. The cloned (but also transgenic) calves, Pampa Mansa II, Pampa Mansa III and
Pampero, developed by the Biosidus Company, carry a gene that produces human growth hormone in milk. The milk
produced by just one cow can meet the demand of the entire country. It is estimated that
1,000 Argentine children currently require such hormone therapy. CONABIA and SENASA approved the first step in the
process to authorize the production of the human growth hormone from milk. The next step that needs to be completed is
approval by the Secretary of Public Health, which is still pending.
The cloned (but also transgenic) calves, Pampa Mansa II, Pampa Mansa III and Pampero, developed by the Biosidus
Company, carry a gene that produces human growth hormone in milk. The milk produced by just one cow can meet the
demand of the entire country. It is estimated that 1,000 Argentine children currently require such hormone therapy.
In 2007, Biosidus Company developed another line of cloned calves, this time to produce insulin. After several years of
research and 4 million dollars investment, “Patagonia” was the first calf born. In this case, the insulin produced by 25 cows
like Patagonia will meet the annual demand of the entire country at a lower cost (30% less than the currently used insulin).
The intention is to produce enough insulin to be able to export in the near future.
And finally in late 2008 with the “Porteña” dynasty, Bio Sidus has accomplished the production of a hormone for bovine
growth from cloned and transgenic calves, which will increase the production of cow milk up to 20%. The country will thus
be the top world producer and exporter of this product. For this project the gene of the hormone for bovine growth was added
to the bovine cells, so that this may be produced inside the udder and secreted to the milk of these animals.
This Porteña dynasty is not focused on the pharmaceutical market but the rural sector, where the hormone for bovine growth
is used to increase the production of milk. Thus, this new product has a totally exporting profile, since it is mainly used in the
USA, Mexico and Brazil, among other countries.
Scientists from the National Agricultural Research Institute (INTA), and from the University of San Martin presented the
first genetically modified calf that has two human genes introduced in its sequence, which guide the production of two
proteins (lactoferrin and lysozyme) contained in human milk. The presence of this proteins in milk, offer infants better
antibacterial and antiviral protection, and also better iron capture than the normal cow’s milk provides.
The calf was born on April 6, 2011, and fifteen months later using lactation artificial induction the scientists confirmed that
both proteins (lactoferrin and lysozyme) are present in its milk.
The regulatory system applied to transgenic animals is the same used to evaluate plant events, that is, the evaluation takes
place on a case-by-case basis. The agencies involved are CONABIA, SENASA, and the National Direction of Agricultural
Food Markets. In the event of evaluations for pharmaceutical use, there is another agency involved, the National
Administration of Medicines, Food and Medical Technology (ANMAT in Spanish).
The norm applied is Number57 from 2003. Original text may be found at:
III. Stakeholder/Public Opinion
There haven’t been reactions in favor or against the development of transgenic animals. The main reason may be that the
first cows produced were intended for pharmaceutical use, and that in general produces less reaction.
IV. Outreach, Needs and Strategies
No activities have been developed specifically on genetic engineered animals.